<DOC>
	<DOCNO>NCT00650754</DOCNO>
	<brief_summary>The experimental focus project interaction DHEA treatment pregnancy woman otherwise unexplained infertility evidence premature ovarian aging ( POA ) .</brief_summary>
	<brief_title>Study Oral Dehydroepiandrosterone ( DHEA ) Treat Previously Unexplained Infertility</brief_title>
	<detailed_description>Recruitment : Eligible patient recruit advertise web newspaper . We screen woman 38 year old regular menstrual cycle one year infertility . Experimental plan : 1 . Informed consent 2 . Baseline study - Antral follicle count Day 2 - 3 cycle - Day 3 Serum FSH , LH , E2 , Prog , DHEA , DHEAS , testosterone , AMH , Fragile X 3 . Randomization pretreatment - Group A : DHEA ( 25 mg three time per day ) - Group B : Placebo 4 . Monitoring treatment - All participant : - USG follicle measurement - Repeat serum , FSH , E2 , DHEA , DHEAS , testosterone , AMH monthly treatment . - Physical examination - Completion study questionnaire regard possible androgen effect treatment 5 . Analysis plan : - Primary Outcome - Pregnancy - Pregnancy rate compare use logistic regression age pre-treatment AMH covariates . - Secondary Outcomes - Endocrine Factors - Androgen side effect - Primary analysis . We perform factorial ANOVA two pretreatment factor DHEA Placebo . Baseline AMH age main covariates - Secondary analysis . - Examine rate change estradiol endocrine response four cycle pretreatment - Compare antral follicle count across pretreatment cycle group - Compare possible androgen relate effect - Power consideration : - Power assumption : alpha 0.05 ; 80 % power - Pregnancy rate unexplained infertility 2 % per cycle . - Intervention improve pregnancy rate 5 % per cycle . - Patients treat 8 cycle . - Cumulative pregnancy rate control patient - 13 % - Cumulative pregnancy rate Treated patient - 30 % - Require 91 patient complete treatment group . - Allow 20 % dropout ( 91* 1.2 ) need 109 patient randomize group . - Randomization : Randomization permute block order maintain even distribution among group ( small number participant ) - Human subject issue - Potential risk associate DHEA use - Potential risk delay treatment 8 month possible natural continue loss fertility - Informed consent issue</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>&gt; = 1 year infertility &lt; 38 year old Normal HSG Normal Semen analysis ( Count &gt; = 20 million/ motility &gt; 50 % / Kruger morph &gt; 14 % . Regular menses Willingness sign inform consent study randomization Willingness participate 8 month nonIVF treatment . Abnormal semen analysis Abnormal HSG Baseline FSH/E2 within normal age specific criterion Medical condition would contraindicate pregnancy , ovulation induction general anesthesia Family history significant genetic disease , factor V leiden thrombophilia Inability present monitoring visit Inability follow medication instruction Desire undergo fertility treatment complete eight month trial</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>DHEA</keyword>
	<keyword>Pregnancy</keyword>
</DOC>